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INTRODUCTION 
 -2- 
Ca2+ channels are transmembrane proteins that, upon membrane 
depolarization, allow the selective passage of Ca2+ ions into excitable cells. 
By controlling the entry of Ca2+ into cells, these proteins have a critical role 
in a broad range of cellular processes, such as neurotransmitter release, 
second messenger cascades, cardiac excitation and contraction, and gene 
regulation supporting learning and memory.1 The Ca2+ channel family 
contains at least ten members that are distinguished by their structure, 
subunit composition, location, biophysical properties and pharmacology. 
According to their electrophysiological and pharmacological properties Ca2+ 
channels are distinguished in N-, L-, T-, P/Q-, and R-type channels.2 Among 
these, the L-Type Ca2+ channel (LCC) has been characterized extensively 
through biochemical approaches. These studies revealed that LCCs are 
heteromultimeric proteins consisting of a central pore-forming α1 subunit 
that expresses the major biophysical, functional and pharmacological 
properties of the channel. This subunit is associated with a number of 
auxiliary subunits, α2δ, β and γ that control channel expression, membrane 
incorporation, drug binding and gating characteristics of the central unit.3 
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Like in the structurally homologous K+ and Na+ channels,4 also the α1 
subunit of LCC is made up by four homologous domains (repeat I-IV) each 
consisting of six transmebrane α-helical segments (S1-S6). The central pore 
of the channel is formed by the S6 segment of each subunit and by the 
extracellular region between S5 and S6 segments (P-loop) that deepens into 
the pore, forming the extracellular mouth of the channel. Four conserved Glu 
residues, in the four P-loops, form the so called EEEE locus which act as a 
selectivity filter for the passage of Ca2+ and other divalent ions.5  
From the pharmacological point of view, LCC represents a realized and 
ongoing opportunity for drug intervention being target of three different 
chemical categories of drugs (Fig. 1): 1,4-dihydropyridines (DHPs such as 
nifedipine), phenylalkylamines (PAAs such as verapamil), and 
benzothiazepines (BTZs such as diltiazem).6  
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Figure 1. General structures of ligands known to antagonize LCC. 
These drugs are used in the treatment of cardiovascular disorders, 
including hypertension, arrhythmias, angina, and cerebral and peripheral 
vascular disorders.7 While verapamil and diltiazem are the only 
therapeutically available members of their respective families, DHPs are well 
represented in a number of second and third-generation agents. The binding 
sites of all these drugs are positioned beneath the selectivity filter and ligand 
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binding studies indicate that PAAs, BTZs, and DHPs bind to three separate 
channel regions that interact allosterically.8 Several studies indicate that 
PAAs reach their binding site from the cytoplasm and are considered to be 
pore-blocking drugs that block LCC directly by occluding the 
transmembrane pore through which Ca2+ ions move. In contrast, DHPs bind 
to a single site at which agonists increase Ca2+ channel activity and 
antagonists reduce it, so they cannot bind in a manner that blocks the pore. 
Therefore, DHP antagonists appear to block the pore indirectly by stabilizing 
a channel closed state with a single Ca2+ ion bound in a blocking position in 
the pore.9 Despite the large body of evidences regarding the specific residues 
involved in the binding of these drugs together with the extensive structure-
activity relationships (SARs) data on the different compounds, it is still not 
absolutely clear how these molecules actually bind to LCC and which are the 
main ligand-LCC interactions responsible for the high affinity to the channel. 
Since the three-dimensional (3D) structure of LCC is not available, different 
theoretical models of this channel were reported and in some of them the 
binding pose of LCC-antagonist was also described. Most precisely, in 
pioneering studies by Lipkind and Fozzard10 and Zhorov and co-workers11 
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the binding pose of DHPs in LCC was obtained by docking a limited set of 
ligands into their putative binding site. It is worth noting that in the first 
study a manual docking procedure was adopted and their reliability could be 
influenced by personal biases and/or ambiguous experimental data. In the 
second study by Zhorov and co-workers nifedipine was docked using a 
Monte Carlo minimization (MCM) method. Indeed, also the small number of 
docked ligands might impede to verify the consistency of the predicted 
ligand-protein complexes with the wide amount of experimental data. 
Therefore in the present study, starting from the above cited studies of 
Zhorov and co-workers, a model of the central pore region of the human 
LCC α1c subunit (Cav1.2) was constructed to get major insights on the 
specific interactions between DHPs antagonist and LCC. Then, the obtained 
3D structure of the LCC inner pore was used for automated docking 
calculations of several DHPs bearing different substituents on the 4-aryl ring 
and on the esters in position 3 and 5 of the DHP ring. As regards the 
construction of the pore region of LCC, the X-ray 3.20 Å crystal structure of 
the bacterial K+ channel KcsA determined by Doyle et al was used.12 In this 
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work all the previous assumptions about the topology of the ion-channel 
superfamily were confirmed, in fact, like Ca2+ channels, KcsA is made up by 
four subunits each consisting of only two transmembrane α-helical segments 
(M1 and M2) rather than six, connected by an extracellular loop (Fig. 2). 
 
 
Figure 2. Ribbon representation of the 3D crystal structure of KcsA. 
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Unlike LCC, KcsA is a homotetrameric rather than an eteromeric protein. 
Nevertheless, it was suggested that this KcsA architecture also describes the 
pore of Na+ and Ca2+ channels and it could be speculated that KcsA is an 
evolutionary predecessor of the six-transmembrane segment ion channels.13 
Thus, it seems reasonable to choose the 3D structure of KcsA as a starting 
point for the construction of both the transmembrane and P-loop regions of 
LCC. More recently, Jiang et al. have determined the 3D structure of the 
open Ca2+-activated K+ channel MthK.14 This structure is almost identical to 
KcsA apart from a hinge region in the M2 segment made of some glycine 
residues critical in the activation of this channel. Considering that voltage-
opened Ca2+ channels have larger residues in the corresponding positions and 
the above cited turning point would note be feasible, the construction of the 
transmembrane portion of LCC using the MthK as a template does not seem 
viable. 
The constructed model of LCC was then used to dock different DHPs. The 
ligand-channel complexes were predicted using an automated docking 
software, AutoDock.15 The choice of this software was dictated by its high 
efficiency in predicting the real experimentally found ligands binding 
 -9- 
conformations.16 This program was used to dock eight different antagonists 
and one agonist DHP featuring molecular diversity (Fig. 4). In such a study, 
in order to distinguish between the two sides of DHPs, as suggested by 
Goldmann et al. the preferred conformation of this ring will be regarded as a 
flattered boat with C4 as the bow, the axial aryl ring as the bowsprit and the 
N1 atom as the stern (Fig. 3a). The two sides of the DHP ring will be then 
referred as the port side (left) and the starboard side (right) (Figure 3b).17 
 
 
Figure 3. General structure of DHP drugs with the adopted nomenclature 
highlighted. 
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The binding mode of nifedipine18 was inspected as it is the most 
structurally representative DHPs that was first introduced as an 
antihypertensive and antianginal agent 30 years ago. (S)-nitrendipine19 and 
lacidipine20 were docked so to evaluate if the presence of the nitro group in 
ortho position or the presence of the large α-β unsaturated ester system on 
the aryl ring could be easily located in the LCC model. DHPs with 
unsymmetrical ester substitution are generally more active pharmacologically 
than those with symmetrical substitution,6,17 therefore, to detect the reasons 
behind this behaviour (S)-isradipine,21 (R)-amlodipine,22 (S,S)-furnidipine23 
and (S,S)-benidipine24 were also docked. In particular, docking of (S)-
isradipine was also performed with the aim of evaluating the influence of the 
benzoxadiazole ring in position 4 on ligand binding. The importance of the 
charged alkyl substituents in position 2 was inspected by docking (R)-
amlodipine, while (S,S)-furnidipine and (S,S)-benidipine were docked in 
order to assess the role on binding of large lipophilic substituents on the port 
side ester group. Some DHP display a peculiar pharmacological behaviour 
when the absolute configuration of their chiral centre at position 4 is changed 
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from the (R)-configuration to the (S)-one. In fact, while the first one has 
antagonist properties towards LCC the latter is an activator of this channel. 
This is the case of Bay K 8644 and for these reasons both isomers of this 
ligands were also docked. Figure 4 reports the structures of the inspected 
compounds. 
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Figure 4. Structures of the investigated ligands
 -13- 
The employment of automated docking procedure allowed to determine at 
atomic resolution the receptor-bound conformations of several DHPs 
endowed of antagonist activity towards LCC. Indeed, the consistency of the 
predicted binding pose of these ligands in LCC with SARs and mutagenesis 
data confirms the feasibility of the calculated binding modes. In this respect, 
the present study gives for the first time a detailed description of the main 
interactions between LCC and DHPs obtained with the employment of an 
automated docking algorithm.
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COMPUTATIONAL METHODS 
 -15- 
Molecular modeling and graphics manipulations were performed using the 
SYBYL 7.225 and InsightII26 software packages, running on a Silicon 
Graphics Tezro workstation equipped with four 700 MHz R16000 
processors. Energy minimizations and MD simulations were realized by 
employing the module Discover326 within InsightII, selecting the 
consistence-valence force field (CVFF).27 
 
Construction of the Human LCC Model. The structural model of the 
human LCC was built using the recently reported 3.20 Å crystal structure of 
KcsA12 (PDB entry code 1BL8) as a structural template. The sequence of 
human LCC pore region α1c subunit (Cav1.2, CAC1C_HUMAN) was 
retrieved from the SWISS-PROT database28 and aligned as described in the 
Results and Discussion section (Figure 5). The construction of the 
transmembrane region of the two alternative models (Model A and B) was 
achieved with the employment of the HOMOLOGY module within InsightII 
which was also used to check the consistence of bond distances, bond angles, 
and torsion angles with proteins standard values. After construction of the 
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transmembrane region of both Model A and B, the whole structures were 
energetically minimized using the Discover326 module of the InsightII suite 
of programs with 5000 steps of a steepest descent minimization reaching a 
convergence of 10.0 kcal mol-1Å-1, followed by 3000 steps of conjugate 
gradient minimization reaching a final convergence of 0.01 kcal mol-1 Å-1 to 
eliminate any residual geometrical strain, keeping the backbone atoms fixed. 
The same procedure was also followed for the construction of the P-loop 
region of LCC (for sequence alignment see Figure 5).  
After construction of both P-loop and transmembrane regions for Model A 
and B the extracellular and transmembrane portion were assembled using the 
a protein-protein docking program. ZDOCK29 software was used for rigid-
body docking of the P-loop on the transmembrane region of LCC. This 
docking method is based on the FFT correlation approach30 that 
systematically evaluates a simple grid-based scoring function over billions of 
relative orientations of the two proteins. ZDOCK scoring function includes a 
combination of shape complementarity, Coulombic electrostatics, and 
desolvation free energy based on the Zhang et al.31 atomic contact potential. 
As default, ZDOCK retains 2000 structures. FFT-based tools are used to 
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rapidly generate a large number of protein-protein conformations with good 
shape complementarity and with relatively favourable electrostatics and 
desolvation values. The top 20,000 structures were retained and ranked by 
the automated Cluspro web server (http://nrc.bu.edu/cluster).32 The 30 
different models achieved from the docking run were then analyzed 
according to the arrangement of the P-loop region on the transmembrane 
bundle. The best solutions for Model A and B were then used as initial 
structure for the subsequent molecular dynamics (MD) simulation. The 
selectivity-filter area of LCC contains eight negatively charged residues 
which are not counterbalanced by any positively charged one. Since Ca2+ 
ions should be the ones that are more present in this channel, four Ca2+ ions 
were added to the P-loop region so to interact with the above cited acidic 
residues. MD calculation was then begun with an initial and equilibration 
stage (500 ps), followed by a production run (1000 ps). In the equilibration 
stage, energy minimization of the protein side chains were achieved 
employing 3000 steps of steepest descent. Subsequently, the system was 
heated gradually starting from 10 to 310 K in 1 ps steps. The system was 
then equilibrated with temperature bath coupling (310 K) applying a 
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tethering force on the backbone starting from 100 kcal/Å-2 and decreasing to 
20 kcal/Å-2. A cutoff of 18 Å was used for nonbonded interactions. 
Coordinates and energies of the production run were saved every 10 ps 
yielding 100 structures. The average structure was calculated over the 100 
structures of the production run and was energy-minimized using 3000 steps 
of a steepest descent minimization keeping the backbone atoms constrained. 
The stereochemical quality of the final structure was analyzed using the 
program PROCHECK.33 
 
Docking Simulations. Docking of nifedipine, (S)-nitrendipine, (S)-
isradipine, (R)-amlodipine, lacidipine, (S,S)-furnidipine and (S,S)-benidipine 
was performed with version 3.05 of the AutoDock software package.15 It 
combines a rapid energy evaluation through pre-calculated grids of affinity 
potentials with a variety of search algorithms to find suitable binding 
positions for a ligand on a given protein. While the protein is required to be 
rigid, the program allows torsional flexibility in the ligand. Docking to LCC 
was carried out using the empirical free energy function and the Lamarckian 
genetic algorithm, applying a standard protocol, with an initial population of 
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50 randomly placed individuals, a maximum number of 1.5 × 106 energy 
evaluations, a mutation rate of 0.02, a cross-over rate of 0.80, and an elitism 
value of 1. Proportional selection was used, where the average of the worst 
energy was calculated over a window of the previous 10 generations. For the 
local search, the so-called pseudo-Solis and Wets algorithm was applied 
using a maximum of 300 iterations per local search. The probability of 
performing the local search on an individual in the population was 0.06, and 
the maximum number of consecutive successes or failures before doubling 
or halving the local search step size was 4. 50 independent docking runs 
were carried out for each ligand. Results differing by less than 1.5 Å in 
positional rmsd were clustered together and represented by the result with 
the most favourable free energy of binding. 
 
Ligand Setup. The core structures of all ligands were retrieved from the 
Cambridge Structural Database (CSD)34 and modified using standard bond 
lengths and bond angles of the SYBYL fragment library. Geometry 
optimizations were realized with the SYBYL/MAXIMIN2 minimizer by 
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applying the BFGS (Broyden, Fletcher, Goldfarb, and Shannon) algorithm35 
and setting a rmsd gradient of the forces acting on each atom of 0.05 
kcal/mol Å as the convergence criterion. Atomic charges were assigned 
using the Gasteiger-Marsili formalism,36 that is the type of atomic charges 
used in calibrating the AutoDock empirical free energy function. Finally, all 
compounds were set up for docking with the help of AutoTors, the main 
purpose of which is to define the torsional degrees of freedom to be 
considered during the docking process. The number of flexible torsions 
defined for each ligand is two for nifedipine, three for (S)-nitrendipine (S)-
isradipine (R)- and (S)-Bay K 8644, seven for (R)-amlodipine, six for 
lacidipine, four for (S,S)-furnidipine, five for (S,S)-benidipine. 
 
Protein Setup. Both Model A and B of LCC were set up for docking as 
follows: only polar hydrogens were added using the biopolymers module of 
the SYBYL program, (Arg, Lys, Glu, and Asp residues were considered 
ionized, while all His were considered neutral by default), and Kollman 
united-atom partial charges were assigned. Solvation parameters were added 
to the final protein file using the addsol utility of AutoDock. The grid maps 
 -21- 
representing the proteins in the actual docking process were calculated with 
AutoGrid. The grids (one for each atom type in the ligand, plus one for 
electrostatic interactions) were chosen to be sufficiently large to include not 
only the active site but also significant portions of the surrounding surface. 
The dimensions of the grids were thus 60 Å × 60 Å × 60 Å, with a spacing of 
0.375 Å between the grid points. 
 
Energy Refinement of DHPs/LCC complexes. Refinement of the 
predicted DHP/LCC complexes was achieved through energy minimizations 
using the Discover3 module of InsightII. These geometric optimizations 
included 5000 steps of a steepest descent minimization reaching a 
convergence of 10.0 kcal mol-1Å-1, followed by 3000 steps of conjugate 
gradient minimization reaching a final convergence of 0.01 kcal mol-1 Å-1, 
keeping the backbone atoms fixed and LCC side-chains and the ligand free 
to move.
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RESULTS AND DISCUSSION 
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Sequence Alignment Between LCC S5s and S6s with KcsA M1 and M2 
Segments 
 
When modeling a protein on a template structure, sequence alignment is 
the most important stage. As regards the construction of a model of the 
central pore of LCC, this task becomes really challenging due to the low 
sequence identity between KcsA and LCC. In consonance with what 
suggested by other authors,10,11 the sequence of the LCC central pore with 
the sequence of KcsA was aligned considering the mutagenesis data present 
in literature on Ca2+-antagonists. Therefore, starting from the assumption that 
ligand-sensing residues are supposed to be located in the same region, the 
best alignment would be the one that maximizes the propinquity of such 
residues. 
In order to detect the interacting residues for dihydropyridines (DHP), 
phenylalkylamines (PAA), benzothiazepines (BTZ) several experimental 
studies (photoaffinity labelling, construction of chimeric channels) where 
reported in literature. This data unambiguously demonstrate that IIIS6 IVS6 
and IIIS5 transmembrane segments interact with the antagonists.37-39 Table 1 
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summarizes results of mutations in LCC segments IVS6, IIIS6, IIIS5 and IIIP 
on binding of a DHP-antagonists (different DHP antagonists were used for 
these reported inspections). 
 
Table 1. Effect on antagonist binding of mutagenesis experiments on LCC. 
Segm
ent 
WT 
Residue 
WT Residue in Human 
LCC 
Mutant 
Residue 
Mutant IC50/WT 
IC50 
Ref. 
Tyr1463 Tyr1508 Ala 6.1 39 
Met1464 Met1509 Ala 1.6 39 IVS6 
Ile1471 Ile1516 Ala 2.7 39 
Ala 25 40 Tyr1152 Tyr1169 
Phe 12.4 40 
Ile1153 Ile1170 Ala 6.2 40 
Ile1156 Ile1173 Ala 17 40 
Met1160 Met1177 Ala 3.5 40 
IIIS6 
Met1161 Met1178 Ala 9.6 40 
Tyr >1000 37, 42 Thr1056 Thr1066 
Ala 1 37,42 IIIS5 
Gln1060 Gln1070 Met 29.4 37, 42 
Phe1112 Phe1128 Ala 5.1 9, 49 IIIP Ser1115 Ser1131 Ala 39.4 9, 49 
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From mutagenesis data, it has been clarified that three amino acid residues 
are critical for the interaction with DHPs in the IVS6 segment Tyr1508, 
Met1509 and Ile1516 and it is likely that these amino acids face the pore.40 
As concerns the IIIS6 segment several residues are responsible for the 
binding with DHPs: Tyr1169, Ile1170, Ile1173, Met1177 and Met1178.41 
Taken together, all this data indicate that DHPs interact with the LCC by 
binding between the IIIS6 and IVS6 helices.42 Mutagenesis data also 
indicated that in IIIS5 residues Thr1066 and Gln1070 are important for 
binding of DHPs.38,43 
With the aim of building an accurate model of the LCC, as suggested by 
Lipkind and Fozzard, two different sequence alignments of the 
transmembrane segments with KcsA can be hypothesized.10 As regards the 
IVS6 segment, it has been proposed to align the M2 Trp87 residue of KcsA 
with the hydrophobic residue Phe1499. This alignment allows Tyr1508 to 
face the pore in accordance with mutagenesis data that demonstrate its 
important role in binding with the DHPs, and locates Ile1173 to form the 
bottom of the putative binding site.10,11 
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For the alignment of IIIS6 segment to M2 of KcsA two possibilities were 
given in the first one Glu1161 is aligned with Trp87 of KcsA. This 
alignment allows placing Tyr1169, Ile1170, Ile1173 Met1177 and Met1178 
at the IIIS6-IVS6 interface. Another sequence alignment can be taken into 
account in which the hydrophobic residue Val1160 is aligned with Trp87; 
this option places both the important residues of IVS6 Tyr1169 and Tyr1508 
at the same level. It is worth noting that with this alignment, residues Ile1170 
and Met178, which mutagenesis data indicate as DHPs interacting residues, 
are placed outside the pore. Indeed, the preference for one of the two 
proposed alignments of the segment IIIS6 of LCC with M2 of KcsA cannot 
be unambiguously determined, hence, two different candidate models were 
built for both alignments of IIIS6. This alternative model will be referred as 
follows: Model A in which Glu1161 is aligned with Trp87of KcsA, Model B 
in which Val1160 of LCC is aligned with Trp87 of KcsA. The predilection 
for one of the two candidates will be ultimately given on the basis of the 
consistency of docking results of DHPs conducted on both models with 
SARs and mutagenesis data.  
 -27- 
Less information are available for segments IS6 and IIS6 so it was 
suggested to align the hydrophobic Trp380 (IS6) and Leu728 (IIS6) with 
Trp87 of KcsA.10 A Gly residue at the C-terminus of the LCC S5 segments is 
really conserved, thus they were all aligned so as to allow this residues to 
coincide with the identical Gly43 of KcsA. Moreover, with this alignment, 
Thr1066 and Gln1070, which are important for the interaction with DHPs,43 
are placed in vicinity of the putative binding site of DHPs, corresponding to 
the position of Thr32 and Leu36, respectively. Figure 5 reports the proposed 
alignment. 
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KcsA
M1 AGAATVLLVIVLLAGSYLA 47
CAC1C_HUMAN
IS5 IALLVLFVIIYAIIGLELF 290
IIS5 LLLLFLFIIIFSLLGMQLF 673
IIIS5 VIVTTLLQFMFACIGVQLF 1071
IVS5 ALLIVMLFFIYAVIGMQVF 1430
KcsA
P ITYPRALWWSVETATTVGYGD 80
CAC1C_HUMAN
IP DNFAFAMLTVFQCITMEGWTD 367
IIP DNFPQSLLTVFQILTGEDWNS 710
IIIP DNVLAAMMALFTVSTFEGWPE 1138
IVP QTFPQAVLLLFRCATGEAWQE 1468
KcsA
M2 WGRCVAVVVMVAGITSFGLVTAALAT 112
CAC1C_HUMAN
IS6 WPWIYFVTLIIIGSFFVLNLVLGVLS 405
IIS6 LVCIYFIILFICGNYILLNVFLAIAV 753
IIIS6 (MODEL A) VEISIFFIIYIIIIAFFMMNIFVGFV 1185
IIIS6 (MODEL B) EISIFFIIYIIIIAFFMMNIFVGFVI 1186
IVS6 FAVFYFISFYMLCAFLIINLFVAVIM 1524
 
Figure 5. Pairwise alignment of CAC1C_HUMAN and KcsA sequences. 
The conserved key residues used to align the sequences are shown in red 
boxes. Residues reported to affect DHPs antagonist binding and underscored 
and highlighted in bold
 -29- 
P-Loops Construction 
 
The extracellular region between M1 and M2 segments of KcsA and 
MthK deepens into the pore, forming a narrow region of 12Å, lined by the 
main chain carbonyl oxygens of the sequence TXGYG acting as selectivity 
filter allowing only the passage of K+ ions.12,14 On the other hand, in LCC 
the side chains of highly conserved Glu residues form a ring called the EEEE 
locus that act as a selectivity filter for the passage of Ca2+ ions. Thus, in 
KcsA permeating cations interact with the backbone carbonyl groups of the 
residues in the selectivity-filter region, while in other P-loop channels ions 
should interact with the side chains of selectivity-filter residues. Hence, it 
was argued that the selectivity filters controlling peculiar features of K+, Na+, 
and Ca2+ channels should have different structures.10 For these reasons, 
several models of LCC were proposed in which KcsA was used as templates 
only for general folding.44 In contrast, in 2005 Zhorov and co-worker 
proposed a model of Na+ channel P-loop region, using MthK coordinates in 
which the P-Loop region shares an almost identical folding of the 
correspondent portion in KcsA.45 These studies clearly demonstrated that 
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experimentally available data on the Na+ channel selectivity-filter region 
could be explained without great modification of the X-ray template of the P-
loop region in MthK. Most precisely, it was demonstrated that 
pharmacological and electrophysiological features of the Na+ channel could 
be reproduced in the model through minor adjustments of the channel 
template in the selectivity-filter region without displacing the entire P-loops. 
This suggests that the P-loop region of voltage gated Na+ channels, of KcsA 
and of MthK have similar 3D structures. Moreover, the same considerations 
could be raised for the P-loop region of LCC. In fact, several experimental 
evidences indicate that the substitution of selectivity filter residues Lys1422 
and Ala1714 in the Na+ channel (forming the DEKA locus) with Glu 
(DEEE) provides Ca2+-selectivity to the channel.46 In addition, this channel 
featured some peculiar pore behaviour of native Ca2+ channels, such as 
permeation by Na+ in the absence of Ca2+.47 Furthermore, the double LCC 
mutant, E1086K/E1387A (human L-type Cav1.2), (EEKA locus) led to a 
channel with pore characteristics analogous to those of Na+.48 
Taken together, these considerations support the use of the 3D coordinates 
of KcsA P-loop region as a template for the construction of the LCC P-
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Loops. It is worth noting that it does not seem viable to model the entire 
extracellular portion between the S5 and the S6 helices. Actually, these large 
loops have different lengths among the four subunits and the little 
experimental data are not sufficient to model the whole region. Possibly, the 
portion between the S5 segments and P-Loops is involved in binding of large 
peptide toxins, but most of drugs of medicinal interest bind at other sites.37-43 
As previously reported, several mutagenesis data suggest that DHPs binding 
site is located between the IIIS6 and IVS6 helices then, ignoring the 
extracellular portion between P-loops and S5 segment is unlikely to affect 
results of the present molecular modeling study, consequently solely the 
LCC extracellular pore region was modelled. 
In order to model the P-loop portion of LCC it was essential to choose a 
proper sequence alignment between LCC and KcsA channels. In this study 
the alignment reported by Tikhonov et al.45 and Yamaguchi et al.46 was used. 
This alignment places Phe1128, Ser1131 and Phe1133 present in P-loop 
repeat III to form part of the putative binding pocket of DHPs. Interestingly, 
this is in accordance with mutagenesis data indicating the important role of 
such residues in the interaction with these ligands.9,50 
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It is worth noting that this alignment places all the Glu residues of the 
selectivity filters at the same level even though several authors suggested an 
asymmetrical alignment so to give explanation for the presence of accessory 
Ca2+ binding sites. On the other hand, pairwise replacement of the four 
glutamates excluded the hypothesis of two high affinity Ca2+ binding sites 
therefore it was concluded that the Glu residues had to be located at the same 
level forming a single selectivity filter ring.50 In order to get a model of the 
LCC pore region each residue of KcsA channel pore region model was 
systematically mutated into the correspondent ones of LCC according to the 
above reported alignment. Afterwards, the structure was energetically 
minimized with the aim of removing all sterically unfavourable contacts. 
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Assembly of the P-Loop Region with the Transmembrane Bundle of 
LCC 
 
After construction of LCC pore region, this portion was adapted on the 
model of the transmembrane bundle of Ca2+ channel. Noticeably, the 
extracellular region of LCC cannot be placed in the same position of KcsA 
and MthK P-loops. In fact, while the highly conserved residue Gly99 in 
segment M2 of KcsA is in close vicinity of the P-loop Ala73,12 in the present 
model Gly99 is replaced by Ile1172 of LCC that, with its bulkier side-chain, 
prevents a similar adjustment in LCC. Therefore, the pore region of LCC 
must be sited higher, closer to the extracellular side of the membrane.10 
In absence of detailed information at atomic level of the specific 
interactions between the P-loop region and the transmembrane bundle of 
LCC accurate and predictive protein-protein docking methods might provide 
substantial knowledge about the 3D structure of this channel. To make 
progress in characterizing the interactions between the transmembrane and 
the outer region of the channel a model of LCC pore region was generated 
performing a rigid-body protein-protein docking of the structure of the P-
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loop region on both Model A and B of the transmebrane bundle using the 
program ZDOCK.29 The choice of this docking software implemented in 
ClusPro server was supported by the outstanding results achieved through 
their employment in the CAPRI experiments where it has shown to be a fast 
and reliable predictor of protein-protein complexes, provided that the 
complex does not undergo a significant structural transformation upon 
binding.51 30 different models were achieved from the docking run and 
analyzed according to the arrangement of the P-loop region on the 
transmembrane bundle. In both docking runs of the P-loop structure on the 
two models (A and B) of the transmembrane region, the top ranking structure 
generated by ZDOCK placed the outer region in a reasonable position, in 
fact, the P-loop portion of each repeat was in both cases adjusted in the 
crevice formed by S5 segment of the same repeat and the S6 segment of the 
adjacent one. All other models generated by ZDOCK were discarded due to 
the implausible binding interactions between the two portions. 
With the intention of building a realistic model of LCC, the generated 
models for candidates A and B were also analyzed to see if they were in 
accordance with experimental data. Actually, mutagenesis experiments allow 
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to infer that the selectivity filter (EEEE locus) is in close proximity of 
Tyr1508.37 In fact, DHP binding is not affected by mutation of residues 
above Tyr1508, thus suggesting that this portion might be in close contact 
with the pore region.37,38 Moreover, when mutating this residue to Ala, the 
reversal potential of the channel is altered by 15mV and permeation of N-
methyl-D-glucamine is increased suggesting that this reside is near the 
selectivity filter.37 
A comparison of the amino acid sequences of the P-loop region of 
different LCCs reveals that all DHP-sensitive channels have a Phe1113 
adjacent to Glu1114 residue of the selectivity filter in the P-loop region of 
repeat III, while all DHP-insensitive channels have a Gly at this position.9 
From mutagenesis experiments conducted by Peterson et al. it could be 
speculated that Phe1113 might be involved in the allosteric coupling of Ca2+ 
binding and DHP binding due to its close proximity to the Ca2+ binding Glu 
residue in the pore.41 Interestingly, in both models Tyr1508 residue is located 
in proximity of the EEEE locus, and really close to Phe1113 engaging with it 
charge transfer interactions. Taken together, these considerations strongly 
support the feasibility of the predicted adjustment of the P-loop on both 
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transmembrane bundle (a representation of the obtained adjustment of LCC 
P-loop in comparison with the KcsA one on the transmembrane bundle is 
given in figure 6). Subsequently, extensive energy minimization and 
molecular dynamics simulations were carried out on the both generated 
candidate models in order to investigate their stability and flexibility (see 
Computational Methods section). 
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Figure 6. LCC model compared with the KcsA crystal structure. LCC 
transmembrane bundle is represented as a white transparent surface, LCC P-
loop is represented as a cyan ribbon while KcsA loop region is represented as 
a green ribbon. 
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DHPs Docking 
 
In order to shed light on the molecular basis of the interactions between 
LCC and its ligands, docking simulations were undertaken on several DHPs 
(chart 1) on both Model A and Model B. Such calculations were conducted 
employing the automated docking program AutoDock which has proven to 
be really effective in reproducing the experimentally found posing of ligands 
into their binding site.15 As shown in Table 2, the 50 independent docking 
runs performed for each ligand usually converged to a small number of 
different clusters (“clusters” of results differing by less than 1.5 Å rmsd). 
Generally, the top clusters (i.e. those with the most favourable ∆Gbind) were 
also associated with the highest frequency of occurrence, which suggests a 
good convergence behaviour of the search algorithm.  
Even if the predicted free energy of binding can be used as tool for the 
choice of the best solution between the different alternative binding positions 
given by the docking software, in this case, the preference for one of them 
was also governed by its consistency with structure-activity relationships 
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(SARs) and mutagenesis data present in literature. In the following section a 
brief description of the calculated binding modes of the selected DHPs into 
both Model A and B is given. 
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Table 2. Result of 50 Independent Docking Runs for Each DHPa 
LCC 
Model Ligand Ntot focc ∆Gbind Surrounding Residues 
Nifedipine 7 23 -8.33 
(S)-Nitrendipine 10 19 -7.94 
(S)-Isradipine 9 17 -7.65 
(R)-Amlodipine 20 14 -8.07 
Lacidipine 20 18 -8.12 
(S,S)-Furnidipine 10 18 -9.49 
(S,S)-Benidipine 23 13 -9.93 
(R)-Benidipine 9 15 -8.74 
A 
(S)-Bay K 8644 13 10 -7,43 
Gln1060 (IIIS5), Phe1061 (IIIS5), Ala1064 
(IIIS5), Phe1128 (IIIP), Ser1131 (IIIP), Thr1132 
(IIIP), Phe1133 (IIIP), Tyr1169 (IIIS6), Ile1170 
(IIIS6), Ile1172 (IIIS6), Ile1173 (IIIS6), Ala1174 
(IIIS6), Phe1176 (IIIS6), Met1177 (IIIS6), 
Met1178 (IIIS6), Ile1180 (IIIS6), Ile1505 (IVS6), 
Tyr1508 (IVS6), Met1509 (IVS6), Ala1512 
(IVS6), Phe1513 (IVS6) 
Nifedipine 5 18 -7.21 
(S)-Nitrendipine 8 15 -7.18 
(S)-Isradipine 6 27 -7.44 
(R)-Amlodipine 24 10 -7.05 
Lacidipine 14 13 -7.00 
(S,S)-Furnidipine 11 21 8.22 
B 
(S,S)-Benidipine 22 14 -8.77 
Gln1060 (IIIS5), Phe1061 (IIIS5), Phe1063 
(IIIS5), Ala1064 (IIIS5), Cys1065 (IIIS5), 
Leu1127 (IIIP), Phe1128 (IIIP), Thr1129 (IIIP), 
Val1130 (IIIP), Ser1131 (IIIP), Thr1132 (IIIP), 
Phe1133 (IIIP), Ile1168 (IIIS6), Tyr1169 (IIIS6), 
Ile1170 (IIIS6), Ile1171 (IIIS6), Ile1172 (IIIS6), 
Ile1173 (IIIS6), Ala1174 (IIIS6), Phe1175 (IIIS6), 
Phe1176 (IIIS6), Met1177 (IIIS6), Phe1504 
(IVS6), Ile1505 (IVS6), Ser1506 (IVS6), Phe1507 
(IVS6), Tyr1508 (IVS6), Met1509 (IVS6), 
Leu1510 (IVS6), Ala1512 (IVS6), Phe1513 
(IVS6), Thr1056 (IVS6), Thr1057 (IVS6) 
 
a
 Ntot is the total number of clusters; the number of results in the top cluster is given 
by the frequency of occurrence, focc; ∆Gbind is the estimated free energy of binding 
for the top cluster results and is given in kcal/mol. The last column shows the 
contacting residues for the binding mode of the best cluster solution calculated 
(S,S)-benidipine. Only residues located within 5 Å from any atom of the docked 
ligand are reported. Residues reported to influence DHP binding are highlighted in 
bold. 
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DHPs Docking on Model A of LCC 
 
Docking of nifedipine, nitrendipine, (S)-isradipine, (R)-amlodipine, 
lacidipine, (S)-furnidipine and (S,S)-benidipine into candidate A gave 
comparable binding solutions with the dihydropyridine ring fitting in the 
cleft formed by IIIS6, IIIS5, and IVS6 segments. Moreover in each docking 
calculation the best solution (in the present case the most consistent with 
SARs and mutagenesis data): i) the plane of the DHP ring is parallel to the 
pore axis, ii) the ligand NH group faces the IIIS5 segment, iii) the starboard 
side of the heterocyclic ring points upwards, iv) the plane of the 4-aryl 
substituent is perpendicular to the pore axis (Figure 7). 
 -42- 
 
Figure 7. Top and side view of docked DHPs in model A of LCC. Ligands 
are represented as orange sticks while LCC is represented as grey ribbons
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This orientation allows the molecules to establish several favourable 
contacts with the channel residues and the great majority these interactions 
revealed to be rather recurrent in the calculated posing of the inspected DHPs 
into the LCC binding site. 
In all inspected ligands the N1 hydrogen atom of the heterocyclic ring H-
bonds with the carbonyl oxygen of Gln1060 side-chain in IIIS5 (Figure 8). 
This is in accordance with both SARs and mutagenesis data. In fact, SARs 
studies indicate that the N1 hydrogen atom has a key role in the binding of 
DHPs to LCC.17 Moreover, a mutational analysis by Mitterdorfer et al. 
clearly demonstrated that Gln1070 contributes to the binding of DHPs.37 
Interestingly, in the same study it was reported that mutation of Gln1070 to 
Asp did not affect the binding of DHPs indicating the participation of the 
glutamine side chain as H-bond acceptor in consonance with the proposed 
binding mode. 
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Figure 8. Docked structures of nifedipine (a), (R)-amlodipine (b), (S,S)-furnidipine (c) and (S,S)-
benidipine in Model A of LCC. DHPs are displayed as white sticks, and key binding site residues are 
shown in green. Hydrogen bonds as represented with dashed blue lines.
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As depicted in Figure 8, both the carbonyl and ester oxygens on the 
starboard side of the dihydropyridine ring form two H-bonds with the 
Ser1131 and Tyr1169 side chains. This is in accordance with SARs data 
indicating the involvement of this group in H-bond interactions with the 
channel.6,17 Moreover, it is also worth noting that the same study indicated 
that also the size of the ester group is important.17 Generally only small sized 
ester groups are tolerated on the starboard side of the DHP ring. This data 
might be rationalized by the fact that the above cited group adapts itself in a 
rather small cleft formed by Tyr1169, Phe1128, Thr1129, Ser1131 and 
Thr1132. Nevertheless, the location of the starboard side ester in this small 
cleft permits the establishing of favourable hydrophobic interactions between 
the methyl or the ethyl group on the DHP ester and Phe1128 side chain 
which has been reported to participate to the binding of DHPs.50 The 
involvement of Tyr1169 in a H-bond with the carbonyl oxygen of the 
starboard side esters of (R)-amlodipine, (S,S)-benidipine and (S,S)-
furnidipine and with the ester oxygen of the same group in nifedipine, (S)-
isradipine, lacidipine and (S)-nitrendipine (see figure 8) is also in agreement 
with mutagenesis data. In fact, when mutating Tyr1169 to Ala (S)-isradipine 
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resulted to be 25 folds less active on the resulting mutant.41 Moreover, when 
Tyr1169 was mutated to Phe (S)-isradipine demonstrated to be 12.4 folds 
less active on the resulting mutant if compared with the wild type channel.41 
This demonstrates the involvement of Tyr1169 hydroxyl group in a H-bond 
with the ligand in agreement with the proposed binding pose. The 
involvement of Ser1131 in the binding of DHPs was demonstrated by 
Yamaguchi et al. who reported that when mutating Ser1131 to Ala the IC50 
value of (S)-nitrendipine was 39.4 times higher than that of rbCII (rat brain 
Ca2+ channel α1C subunit type II).50 
The 4-aryl substituent of the docked DHPs is in close contacts with 
Tyr1508 engaging with this residue a T-shaped charge transfer interaction. 
Also in this case the involvement of Tyr1508 in the binding of LCC DHPs 
antagonists was experimentally proven by mutagenesis studies. In fact, 
replacement of this residue to Ala has large effects on DHP activity with the 
KD for DHP binding in Tyr1508Ala mutant increased by 6.1 folds.38 
Extensive SARs studies have unambiguously demonstrated that electron-
withdrawing substituents in the 4-phenyl ring enhance activity in the ortho 
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and meta positions while any substituent in the para position is 
detrimental.6,17 This data can be rationalized by the proposed posing in fact a 
substituent in para position to the phenyl ring would give unfavourable steric 
clashes with the backbone atoms of Tyr1508 and Met1509 while substituents 
in both ortho and meta positions have enough space in the binding pocket. 
The ester group on the port side of the DHP ring adopts a cis conformation 
to the double bond of the heterocyclic ring. The trans conformation does not 
appear to be feasible due to the unfavourable steric clashes that the large port 
side esters would give with IIIS6 segment. Indeed, synthesis of DHP 
derivatives with an immobilized ester groups demonstrated the preference 
for a cis conformation of the port side ester. It is worth noting that the large 
lipophilic substituents on the port side ester establish favourable hydrophobic 
interactions with Met1177 and Met1178 which have been shown to 
participate to the binding of DHPs.41 Alternatively, the same substituent 
points towards the centre of the pore, establishing pi-pi charge transfer 
interactions with Phe1133 as in case of (S,S)-benidipine. Noticeably, 
lacidipine has a small port side ester although in this case the large lipophilic 
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substituent present in ortho on 4-phenyl ring occupies the same region of the 
above cited groups. 
The entire DHP ring adapt itself on Ile1173 side-chain establishing with it 
favourable hydrophobic interactions. This data also agrees with mutagenesis 
studies indicating that mutation of Ile1173 to Ala results in a loss of potency 
on DHPs of 17 folds. 
As regards positions 2 and 6 of the DHP ring, the majority of the analyzed 
drugs are characterized by the presence of methyl substituents. The only 
exception is found in (R)-amlodipine (Figure 8b) in which the flexible 
aminoethyloxymethyl group through its protonated amine atom H-bonds 
with Gln1060 side chain carbonyl oxygen. 
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DHPs Docking on Model B of LCC 
 
The binding orientation of the docked DHPs into model B of LCC roughly 
resembles one found for model A. In fact, as calculated by AutoDock, the 
DHP ring locates itself in the fissure between segments IIIS6, IIIS5 and IVS6 
with the heterocyclic ring adapted in the same orientation found in model A 
with respect to the pore axis. If compared with results of DHPs docking on 
Model A, AutoDock was able to find basically the same sort of interactions 
when docking was performed on Model B of LCC. In fact, i) the N1 
hydrogen atom of the DHP ring H-bonds with the carbonyl oxygen of 
Gln1060 side chain, ii) the carbony oxygen of the starboard side ester H-
bonds with the hydroxyl group of Ser1131 side chain, iii) the ester on the 
port side of the DHP ring is favourably positioned in a cis orientation to the 
ring double bond so to allow the large ester portion to point towards the 
centre of the channel pore (Figure 9). This orientation permits the 
establishing of favourable hydrophobic interactions with Ile1173 and 
Met1177 which were reported to influence the DHP binding.41
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Figure 9. Docked structures of nifedipine (a), (R)-amlodipine (b), (S,S)-furnidipine (c) and (S,S)-
benidipine in Model B of LCC. DHPs are displayed as white sticks, and key binding site residues are 
shown in green. Hydrogen bonds as represented with dashed blue lines. 
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Indeed, the different alignment of the IIIS6 portion implicates the presence 
of different interactions with this segment. The most striking difference in 
the DHP binding to Model B of LCC resides in the absence of any 
interaction between the ligand and Tyr1169 which, as already mentioned, 
plays a crucial role in the recognition mechanism of DHP to LCC.41 
Additionally in Model B, apart form Ile1173, the essential residues Met1177, 
Met1178 and Met1175 are placed far away from the docked DHPs. 
From this point of view, the present calculations strongly indicate that the 
sequence alignment between IIIS6 of LCC and M2 of KcsA in Model B 
could be unable to produce all the essential interactions with the DHP ring in 
the calculated binding pose. In this respect, the sequence alignment of IIIS6 
in Model A appears to be more in accordance with experimental findings 
such as SARS and mutagenesis data. Actually, the presence of two 
alternative sequence alignments was also reported in a previous paper by 
Lipkind et al. who gave the preference to candidate B rather than the A 
one.10 This decision was in the end dictated by correspondence between the 
proposed DHP binding mode in LCC and mutagenesis data. In fact, in this 
study nifedipine, (–)-Bay K8644 (LCC agonist), a derivative of nifedipine 
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with an isopropyl ester group on the port side and a DHP with fused 
thiophene ring were manually docked into LCC. Possibly, it could be 
hypothesized that manual docking exercises always require some subjective 
decisions, and there is the danger that personal biases, ambiguous 
experimental data, or misinterpretation of experimental results could corrupt 
the manual ligand-docking exercises. On the contrary, in the present study 
docking calculation of DHPs into LCC were all performed employing an 
automated docking software such as AutoDock. Hence, discrepancies 
between the sequence alignment suggested by Lipkind et al. and the one 
proposed herein could have arisen due to the different docking approaches 
adopted. 
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From Antagonist to Agonist DHPs 
 
In this theoretical study a peculiar pharmacological behaviour of some 
DHPs was also rationalized. In fact, it is well known that some of these 
compounds exhibit an interesting stereoselective duality of action, with one 
enantiomer behaving as an agonist and the other one having antagonist 
properties. Indeed, these LCC activators do not have any therapeutic role, 
nevertheless they represent one of the incongruities of the medicinal 
chemistry. For these reasons, both the antagonist (R)-enantiomer and the 
agonist (S)-enantiomer of Bay K 864452 were also docked. 
As expected, the predicted posing of (R)-Bay K 8644 into Model A of 
LCC strongly resembles the previously described ones establishing the same 
polar and hydrophobic interactions found for the previously mentioned 
antagonists (Figure 10a). It is worth noting that the vicinity of the ligand port 
side ester with the hydrophobic residues at the crevice between the of IIIS6 
and IVS6 segments could impede the conformational rearrangements of 
these segments thus stabilizing the inactivated state of the channel.42 In fact, 
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it is well known that voltage-gated channels seem to open by movement of 
the inner parts of the S6 α-helices.53 
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Figure 10. Docked structures of (R)-Bay K 8644 (a) and (S)-Bay K 8644 (b) in Model A of LCC. 
DHPs are displayed as white sticks, and key binding site residues are shown in green. Hydrogen 
bonds as represented with dashed blue lines 
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Also for the (S)-enantiomer of Bay K 8644 the calculated posing was 
pretty similar with what already found for the (R)-one and this is in 
accordance with experimental data suggesting that both DHP agonist and 
antagonists should share the same binding site.42 Obviously, the different 
absolute configuration of the chiral centre in position 4 allows different 
interactions with LCC. In fact, in this case the nitro group on the port side 
faces the bottom of the channel pore while the starboard side points outwards 
H-bonding with Ser1131 and Tyr1169 (Figure 10b). The main differences in 
the calculated binding mode of (S)-Bay K 8644 with respect to the (R)-one 
mainly resides in the absence of any interaction with the hydrophobic 
residues present at the intersection between the III and IVS6 segments in 
which the main structural rearrangement occur during the channel opening. 
Therefore, the lack of such an interaction could explain the reasons for the 
absence of any antagonist activity of this enantiomer towards. Moreover, the 
latter ligand exposes his hydrophilic nitro group to an hydrophobic surface at 
the junction of the S6 segments of repeat III and IV in the closed state, 
making such an interaction energetically unfavourable. Therefore, it could be 
hypothesized that the agonist could destabilize the closed state of LCC and 
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could stabilize the opened one. Further studies should be undertaken to 
elucidate the conformation of the channel in the open state and then use it to 
dock the agonist ligands eventually confirming such an hypothesis.  
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CONCLUSIONS 
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In this contribution results of a computational study on the human cardiac 
L-Type Ca2+ channel which is one of the most important biological targets of 
pharmaceutical interest are reported. A 3D model of this channel was built 
using the crystallographic structure of KcsA as a template considered to be a 
predecessor of the six-transmembrane segment ion channels. Extensive 
mutagenesis data present in literature LCC allowed to perform a pairwise 
alignment between the sequences of the two proteins leading to two different 
arrangements which were used to construct two candidate models of LCC 
(Model A and B). After construction of the transmembrane bundle and P-
loop region of LCC alone, the latter was adapted on the intracellular portion 
through rigid-body protein-protein docking calculations. Both Model A and 
B were then comprehensively validated employing MD simulations. 
Automated docking simulations were then conducted using both Model A 
and B on nine different DHP antagonists featuring molecular diversity. These 
calculations allowed to detect the presence of a similar posing in both 
theoretical models in which: the plane of the DHP ring is parallel to the pore 
axis, the ligand NH group faces the IIIS5 segment, the starboard side of the 
heterocyclic ring points upwards and the plane of the 4-aryl substituent is 
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perpendicular to the pore axis (Figure 7). Despite the comparable binding 
orientation of DHPs antagonists in both candidates, dissimilar interaction 
patterns were detected between ligands and LCC with the most prominent 
difference residing in the lack of specific interactions with the IIIS6 segment 
in Model B. In particular, in this structure the ligand is unable to interact 
with Tyr1169 residue which was reported to have a key role in the 
interaction with DHP antagonists.41 In this respect, the coherence between 
docking results obtained with structure A and SARs and mutagenesis data 
would drive the preference towards this candidate rather than the B one. In 
fact the correlation between the predicted binding pose in Model A and the 
large body of evidence regarding mutagenesis information for the protein and 
SARs data for ligands demonstrated that this model is very realistic and 
reveals an insight into the binding pose of DHPs antagonists. In particular, 
these drugs fit into LCC binding site adopting a sort of “spider” 
conformation (seer Figure 8) with the DHP ring resembling the body of the 
animal and the substituents in position 2, 3, 5 and 6 resembling the legs. This 
arrangement allows the formation of several H-bond interactions with LCC 
through their NH group with the carbonyl oxygen of Gln1060 side-chain and 
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through their starboard side ester oxygens with Ser1131 and Tyr1169 side 
chains. Moreover, the same ester points in a rather small cleft formed by 
Tyr1169, Phe1128, Thr1129, Ser1131 and Thr1132. The 4-aryl substituent of 
the docked DHPs is in close contacts with Tyr1508 engaging with this 
residue a T-shaped charge transfer interaction and the adjacent port side ester 
group, adopting a cis conformation, points towards the centre of the pore 
establishing favourable hydrophobic interactions with Met1177, Met1178 
and Phe1133. Additional hydrophobic interactions are also engaged by the 
entire DHP ring and Ile1173 side chain.  
The described posing of DHP antagonist into LCC inner pore might also 
help in suggesting a possible mechanism of action. In fact, LCC is believed 
to open through a movement of the C-terminal part of S6 segments of each 
repeat resulting in a widening of this region that allows the passage of Ca2+ 
ions.53 In the predicted binding pose of the selected DHPs the port side ester 
establishes favourable hydrophobic interactions with the lipophilic C-
terminal residues of IIIS6 and IVS6 segments. Therefore, it might be 
speculated that such an interaction might stabilize the inactivated state of 
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LCC by preventing the relocation of IIIS6 and IVS6 segments required for 
the opening of the channel. 
In conclusion, herein a molecular modeling study aimed at providing both 
a structural model of LCC central pore and a detailed description of the 
posing of DHPs antagonists into the channel binding site has been presented. 
Such model provided plausible hypotheses for ligand-channel interactions 
satisfactorily explaining the large body of SARs data available in literature 
and revealing the key residues that interact with ligands. Further studies in 
this direction would validate this model, which could subsequently be used 
for de novo drug design. It is worth noting that the validity of this theoretical 
model relies on some assumptions and remains speculative. However, the 
coherence of many observations on the 3D models might not be fortuitous. 
Furthermore, only the central pore of LCC was constructed and a complete 
model of the channel α1 subunit would also require inclusion of additional 
helix per repeat, for which no structural template exists. Though, none of 
these issues is insurmountable.54 
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